1346604-70-3

Basic information

• Product Name: CANDESARTAN-D4
• Synonyms: CANDESARTAN-D4;2-Ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1-(phenyl-d4)-1'-phenyl]-4-yl]Methyl]-1H-benziMidazole-7-carboxylic Acid;Candesartan M1-d4;CV-11974-d4
• CAS NO: 1346604-70-3
• Molecular Formula: C₂₄H₂₀N₆O₃
• Molecular Weight: 444.48
• Product Categories: Aromatics;Bases & Related Reagents;Intermediates & Fine Chemicals;Isotope Labelled Compounds;Nucleotides;Pharmaceuticals
• Mol File: 1346604-70-3.mol

Chemical Properties

• Appearance: /
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly, Heated)
• CAS DataBase Reference: CANDESARTAN-D4(CAS DataBase Reference)
• NIST Chemistry Reference: CANDESARTAN-D4(1346604-70-3)
• EPA Substance Registry System: CANDESARTAN-D4(1346604-70-3)

Safety Data

• Hazardous Substances Data: 1346604-70-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Candesartan-D4 is used as an internal standard for the quantification of candesartan in pharmaceutical research and development. It aids in the accurate measurement and analysis of candesartan levels in various formulations, ensuring the efficacy and safety of the drug.
Used in Treatment of Congestive Heart Failure:
Candesartan-D4, as an active metabolite of candesartan cilexitil, is employed in the treatment of congestive heart failure. It acts as an angiotensin II type-1 receptor antagonist, helping to improve the symptoms and outcomes for patients suffering from this condition.
Used as an Antihypertensive:
Candesartan-D4 is also used in the treatment of hypertension. By blocking the angiotensin II type-1 receptor, it helps to lower blood pressure and reduce the risk of cardiovascular events in patients with high blood pressure.

Upstream product

• 1420880-36-9 2-cyano-2',3',5',6'-tetra-[²H]-4'-methyl-biphenyl 
• 1420880-35-8 4, 4-dimethyl-2-(2',3',5',6'-tetra-[²H]-4'-methyl-biphenyl-2-yl)oxazoline 
• 57598-33-1 2-(2-methoxyphenyl)-4,4-dimethyl-2-oxazoline 
• 112484-85-2 2,3,5,6-tetra-[²H]-4-bromo toluene 
• 1420880-46-1 ethyl 1-((2'-cyanobiphenyl-4-yl)(2,3,5,6-tetra-[²H]-methyl))-2-ethoxy-1H-benzo[d] imidazole-7-carboxylate 
• 1420880-45-0 ethyl 3-amino-2-((2'-cyanobiphenyl-4-yl)(2,3,5,6-tetra-[²H]-methyl)amino)benzoate 
• 1420880-44-9 ethyl 2-((2'-cyanobiphenyl-4-yl)(2,3,5,6-tetra-[²H]-methyl)amino)-3-nitrobenzoate 
• 1420880-43-8 ethyl 2-(tert-butoxycarbonyl((2'-cyanobiphenyl-4-yl)(2,3,5,6-tetra-[²H]-methyl))amino)-3-nitrobenzoate 
• 1420880-42-7 2',3',5',6'-tetra-[²H]-4'-(bromomethyl)biphenyl-2-carbonitrile 

Relevant articles and documents

Synthesis of deuterium-labeled olmesartan and candesartan

This paper describes the synthesis of deuterium-labeled olmesartan and candesartan. The two desired compounds both used [2H4] 2-cyano-4'-methyl-biphenyl as deuterium-labeled reagent, which was synthesized beforehand in two steps. [2H4] olmesartan was synthesized in six steps further with 17% overall yield, and [2H4] candesartan was synthesized in seven steps further with 13% overall yield. Copyright 2012 John Wiley & Sons, Ltd. This paper describes the synthesis of deuterium-labeled olmesartan and candesartan. The two desired compounds both used [2H4] 2-cyano-4'-methyl-biphenyl as deuterium-labeled reagent, which was synthesized beforehand in two steps. [ 2H4] olmesartan was synthesized in a further six steps with a 17% overall yield, and [2H4] candesartan was synthesized in a further seven steps with a 13% overall yield. Copyright